Concerns Over Muscle Loss with GLP-1 Weight Loss Drugs (LLY, NVO, REGN)

Clinical studies highlight that Eli Lilly (LLY, Financial) and Novo Nordisk's (NVO) weight loss drugs result in significant lean body mass reduction, with 25% and 40% of weight loss attributed to muscle loss, respectively. In response, Regeneron (REGN) is researching a new drug aimed at mitigating muscle loss caused by weight loss medications. While drugs like Ozempic and Wegovy have spurred a "gold rush" in the pharmaceutical industry, George Yancopoulos, co-founder of Regeneron, warns of potential muscle ...